ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, reaching US$ 878.9 Million in 2024 and an impressive US$ 1,569.2 Million by 2030.

The latest episode “Made in the USA” podcast explores a company that uses collaborative robots, one of the key tools helping US machine shops and other manufacturers compete with lower cost countries ...

CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD ... Engagement on RMD's patient app (myAir) indicates ongoing momentum in therapy compliance, noting the potential of the rate of OSA diagnosis to ...

A heart-lung machine is a piece of medical equipment that temporarily takes over the work of the heart and lungs, circulating oxygenated blood throughout the body. Also called a cardiopulmonary bypass ...

The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, reaching US$ 878.9 Million ...

Learn More ResMed Inc. (ASX: RMD ... Engagement on RMD's patient app (myAir) indicates ongoing momentum in therapy compliance, noting the potential of the rate of OSA diagnosis to step up from ...